The submitting company did not present a sufficiently robust economic analysis to gain acceptance by SMC.
Similarly, in their guidance, NICE did not recommend darvadstrocel, within its marketing authorisation, for previously treated complex perianal fistulas in adults with non-active or mildly active luminal Crohn's disease, for the same reason.